Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Two Doses of Ocrelizumab in Active Systemic Lupus Erythematosus
2006-005355-16Phase 3Terminated
- Sponsor
- Roche
- Start
- Aug 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ocrelizumab in systemic lupus erythematosus (SLE) (3 arms), sponsored by Roche. Primary endpoint: Clinical response categories at Week 48. Started Aug 2007; status: terminated.
02
Drugs
ocrelizumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2006-005355-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005355-16.